DxS develops Erbitux companion test for BMS, ImClone
DxS (oncogene mutation kits) has agreed to develop a TheraScreen companion diagnostic for ImClone Systems' metastatic colorectal cancer product Erbitux (cetuximab), which is sold by Bristol-Myers Squibb. BMS and ImClone will have rights in the US and Canada.
- In Vitro Diagnostics
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.